GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study to Evaluate Avastin in Combination With Standard Chemotherapy to Treat Colorectal Cancer
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-04-25
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT00109070
An Extension Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer Study
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-04-25
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT00109057
A Study of Patients With HER2-Positive Metastatic Breast Cancer
Completed
- Conditions
- First Posted Date
- 2005-03-15
- Last Posted Date
- 2010-05-06
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 1000
- Registration Number
- NCT00105456
A Study of Avastin With Chemotherapy for Treatment of Metastatic or Advanced and Unresectable Colorectal Adenocarcinoma
Completed
- Conditions
- First Posted Date
- 2004-11-25
- Last Posted Date
- 2013-03-28
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 1953
- Registration Number
- NCT00097578
- Locations
- 🇺🇸
Genentech Central Contact, South San Francisco, California, United States
A Study to Evaluate Subjects With Turner Syndrome Treated With Growth Hormone
Completed
- Conditions
- First Posted Date
- 2004-11-25
- Last Posted Date
- 2012-11-14
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 1696
- Registration Number
- NCT00097552
Bone Mineral Density (BMD) in Adolescents With Growth Hormone Deficiency (GHD)
Completed
- Conditions
- First Posted Date
- 2004-11-25
- Last Posted Date
- 2012-11-14
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 125
- Registration Number
- NCT00097526
A Study in Children With Growth Failure Due to Chronic Renal Insufficiency (CRI) or End Stage Renal Disease (ESRD)
Completed
- Conditions
- First Posted Date
- 2004-11-25
- Last Posted Date
- 2012-11-14
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 395
- Registration Number
- NCT00097617
National Cooperative Growth Study (NCGS): A Post-marketing Surveillance Program for Nutropin, Nutropin AQ, Nutropin Depot, and Protropin
- First Posted Date
- 2004-11-25
- Last Posted Date
- 2017-02-15
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 65205
- Registration Number
- NCT00097539
National Cooperative Growth Study (NCGS) of Optimal Nutropin AQ and Nutropin Dosing in Pubertal Growth Hormone-Deficient (GHD) Patients
Completed
- Conditions
- First Posted Date
- 2004-11-25
- Last Posted Date
- 2010-11-15
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT00097513
- Locations
- 🇺🇸
Genentech Central Contact, South San Francisco, California, United States
An Observational Study of Treatment, Outcomes, and Prognosis in Patients With Follicular Non-Hodgkin's Lymphoma
Completed
- Conditions
- First Posted Date
- 2004-11-25
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 2740
- Registration Number
- NCT00097565
© Copyright 2024. All Rights Reserved by MedPath